Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis

NCT01453764 is registered in ClinicalTrials.gov with Ageless Regenerative Institute as lead sponsor.

NCT NCT01453764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis
Lead sponsor
Ageless Regenerative Institute
Phase
Not applicable
Overall status
Withdrawn
Start date
April 30, 2016
Completion date
April 30, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, autoimmune diseases of the nervous system, multiple sclerosis, nervous system diseases